Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
A Phase 1, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness of AlphaMedix™ in Adult Subjects With SSRT(+) NETs.
Sponsor: Orano Med LLC
Terminated
Terminated for non-safety reasons.
A PHASE1 clinical study on Neuroendocrine Tumor, this trial is terminated or withdrawn. The trial is conducted by Orano Med LLC and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Jul 2025 — Present [monthly]
Terminated PHASE1
Status: Unknown → Terminated
-
Sep 2024 — Jul 2025 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Sep 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Sep 2021 — Sep 2023 [monthly]
Recruiting PHASE1
▶ Show 7 earlier versions
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Feb 2020 — Aug 2020 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Sep 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2019 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Feb 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Orano Med LLC
For direct contact, visit the study record on ClinicalTrials.gov .